Boule Diagnostics AB (BOUL.ST) Stock Analysis & Winston Score
Boule Diagnostics is a Swedish medical device company that makes blood analysis machines and the test supplies that go with them. Their instruments count and measure the different types of cells in a blood sample — a common test used in hospitals and clinics to diagnose infections, anemia, and other conditions. Boule focuses on smaller, affordable analyzers designed for clinics and labs in emerging markets like Africa, Latin America, and parts of Asia. The company earns money by selling both the machines and the consumable reagents — the chemical liquids needed to run each test — which creates a recurring revenue stream after the initial instrument sale. Boule operates globally but generates a significant share of revenue outside wealthy Western markets, where low-cost, easy-to-use devices have a competitive edge. The negative ROIC signals the business is currently struggling to generate returns above its cost of capital, and the key challenge ahead is scaling volume in developing markets while keeping costs under control.
Winston Score: 24/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (6/30)
- Growth: Weak (3/20)
- Cash Flow: Weak (1/10)
- Stability: Mixed (3/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $3.45
Market Cap: $134M
Sector: Healthcare
Industry: Medical - Specialties
Exchange: Stockholm Stock Exchange

